Does PRP Really Stop Hair Loss?

Short Answer: Does PRP Stop Hair Loss?

Partly yes — conditionally. Hair PRP (platelet-rich plasma) slows the rate of shedding and produces a measurable increase in hair shaft diameter in roughly 60–70% of patients with early-to-moderate androgenetic alopecia. In the remaining 30–40%, no significant change is observed. PRP does not regenerate lost follicles; it supports follicles that are still alive but beginning to miniaturise.

This article conveys what the literature and day-to-day clinical practice say — not what marketing campaigns promise. If any of the following questions brought you here, you are in the right place: I have seen PRP advertisements — does it genuinely work? Should I have a hair transplant, or can I stop the loss with PRP? Will my hair return to how it was after three sessions? Our hair PRP service page contains the full technical protocol; this article provides a realistic framework for making your decision.

What Does PRP Do to the Scalp? The Biological Mechanism

Understanding PRP requires looking at three things in order: what it is, how it is prepared, and which cells it stimulates in the scalp.

PRP is a plasma fraction prepared from the patient's own blood. Twenty millilitres of blood drawn from your arm are spun in a centrifuge for 10–15 minutes; the blood separates into three layers (red blood cells, plasma, and the platelet-rich middle layer — the buffy coat). This middle layer is the active component; platelet concentration is 3–5 times higher than in whole blood. It is an autologous (self-sourced) product: there is no biological risk of immune reaction, rejection, or cross-infection.

Platelets do far more than clotting. Granules stored within them contain growth factors that carry the tissue-repair signal: PDGF (cell proliferation), VEGF (new capillary formation — the key to follicle nourishment), TGF-β (tissue remodelling), IGF-1 (dermal papilla activation, prolonging the anagen phase), EGF and FGF (cell growth, vascular tone).

In the scalp these signals act at three points. First, they stimulate the dermal papilla — the follicle's "command cell" — prolonging the hair's growth (anagen) phase. Second, they increase the density of the capillary network surrounding the follicle; a better-nourished follicle produces a higher-quality hair shaft. Third, they reduce the rate of miniaturisation that gradually thins the follicle in androgenetic alopecia.

A critical boundary: PRP can only support follicles that are still alive. A fully closed follicle whose niche has collapsed cannot resume hair production regardless of how many growth factors are delivered. This biological reality also defines the limit of who PRP helps — and who it does not.

What Does the Literature Say? Numbers, Not Marketing

Meta-analyses and randomised controlled trials on PRP in androgenetic alopecia published over the past decade paint a reasonably consistent picture. "Consistent" is the critical word here, though: there is a response — but it is not universal.

What the literature tells us:

• An average increase in hair density of 15–30% is reported. This is the measurement difference between baseline and month six; the magnitude varies between patients.
• An increase in hair shaft diameter (terminal hair ratio) is observed — the conversion of vellus hairs to terminal hairs is confirmed by microscopic trichoscopy.
• A reduction in the rate of shedding is consistently observed across most studies; a pull test in the PRP group yields fewer hairs than in the control group.
• Response rate of approximately 60–70% — most patients achieve a visible benefit; the remaining group does not respond adequately to treatment.
• Follow-up window of 3–6 months. It is not possible to judge "it worked / it did not work" before this period; the biological response takes time.

What the literature does not tell us: which PRP kit is superior, how long the effect lasts without maintenance, or the "optimal" protocol (number of sessions, interval, injection pattern) — there is no standard; each clinic applies its own variation. Differences in kit brand and platelet concentration ratios make comparing studies difficult; clinical practice observes that without maintenance, the effect weakens within 12–18 months.

The clear take-away: PRP has been shown to work in androgenetic alopecia, but the promise of "dramatic results for every patient" does not come from the literature. A realistic expectation is a 60–70% probability of response, with slower shedding and increased thickness in those who do respond. This is not a miracle; but it is a meaningful difference compared with doing nothing.

Who Benefits and Who Does Not? The Candidacy Reality

The most frequent source of disappointment with PRP is applying it to the wrong patient with the wrong expectation. The table below summarises the decision matrix we work through together during consultation.

Why is early-to-moderate stage so decisive? PRP targets follicles that are still active. At Norwood 2–4 or Ludwig 1–2, the follicle has thinned but its niche is alive; growth factors can stimulate stem cells. At Norwood 5–7, the follicle has largely disappeared — it is not a "hairless area" but a "follicle-free area". Injecting PRP into such an area is like spreading fertiliser on an empty plot: the soil may be ready, but there are no seeds. The solution is follicle transfer from the donor area via FUE or DHI.

Telling a patient who came expecting a hair transplant but is found at early-to-moderate stage, "let us try PRP plus medication first and reassess at six months"; and telling a patient who came expecting PRP but is found to be at an advanced stage, "PRP is not the right option for you" — this two-directional honesty defines our approach to patient selection.

PRP Alone Is Not Enough: The Minoxidil and Finasteride Reality

In hair-loss treatment, marketing easily falls into the trap of "do not use medication instead of PRP" or "natural PRP as an alternative to drugs." These two approaches are not opposites — they are complementary. This section contains the strongest signal in the literature.

Minoxidil (topical — 2% or 5%) is one of only two licensed treatments for androgenetic alopecia. It increases follicular vascularity and prolongs the anagen phase. Its systemic side-effect profile is low; the most common side effects are scalp itching at the application site and a short-term increase in shedding — known as "shedding" — during the first 2–3 months (which stabilises thereafter).

Finasteride (oral — 1 mg/day) is the second licensed treatment for male-pattern hair loss. It inhibits the 5-alpha reductase enzyme, blocking the conversion of testosterone to DHT; DHT is the primary driver of follicle miniaturisation in the androgenetic process. Its efficacy is significant; sexual side effects are reported in a small percentage of patients and require thorough patient counselling. It is contraindicated in women of childbearing potential.

Why is the PRP + medication combination more effective?

• Minoxidil acts via a chemical pathway: it affects follicular vascularity and anagen duration.
• Finasteride works at the hormonal level: it reduces the DHT burden.
• PRP is a biological stimulus: it activates the dermal papilla and the stem cell niche.

Three distinct mechanisms stack on top of one another; the effects accumulate. In randomised studies, the PRP + minoxidil arm showed a greater increase in hair density than the minoxidil-only arm. Equally, PRP + finasteride produced a more pronounced increase in terminal hair ratio than finasteride alone.

What do we recommend in practice? After discussing expectations and side-effect profiles during consultation, one of the following plans emerges:

• Mild shedding + concern about side effects: Minoxidil 5% + PRP (first choice; lowest side-effect profile).
• Moderate-to-advanced shedding + male patient who accepts side effects: Finasteride + Minoxidil + PRP (strongest combination).
• Female patient (not of childbearing potential, appropriate endocrine profile): Minoxidil + PRP; low-dose oral minoxidil or spironolactone may be considered alongside, under dermatologist guidance.
• Postpartum telogen effluvium: iron/ferritin + thyroid + B12 check → correction of underlying cause → PRP as adjuvant.

The approach of "I will have PRP and skip medication" deviates from the literature; a one-sided treatment will not meet expectations.

Hair Transplant or PRP? The Decision Matrix

One of the most frequent questions in consultation: "If I have PRP, will that be enough — do I actually need a hair transplant?" The answer depends on the stage of loss and donor capacity. Let us work through three scenarios.

Scenario 1 — Early stage (Norwood 2–3, Ludwig 1): PRP plus medication is the first choice. A hair transplant at this stage is premature — because the loss process has not stabilised, natural hair behind the transplanted area continues to thin, creating a risk of a patchy appearance. The aim is to slow the loss; reassess after 12–24 months.

Scenario 2 — Moderate stage (Norwood 3–4, Ludwig 2): The decision depends on two factors. If the loss pattern has stabilised and the patient wants rapid cosmetic improvement, a hair transplant may be appropriate. If shedding is actively progressing, first stabilise with PRP plus medication and review at month 12. Transplanting onto a stable baseline always produces better long-term outcomes than transplanting onto active loss.

Scenario 3 — Advanced stage (Norwood 5–7, Ludwig 3): PRP alone is not a solution; there are no target follicles remaining. Hair transplantation is the primary intervention; FUE or DHI is planned if donor supply is adequate. PRP moves into an adjuvant role: 1–2 sessions of donor preparation before the procedure, then 3 sessions afterwards (at months 1, 3, and 6) to support graft viability and manage shock loss. We integrate this combination into both our FUE and DHI packages.

Why do hair transplantation and PRP work well together? Grafts experience a temporary shedding event in the first 2–6 weeks known as "shock loss" — this is part of the adaptation process, not a loss of follicles. PRP's growth factors support follicle nourishment during this period, accelerate vascularisation, and may reduce the severity of shock loss. Clinical observation that hair emergence is more pronounced at month six in the PRP-combined group is supported by small studies in the literature.

The decision is not an "either/or" matter. Depending on the stage, PRP alone may suffice; at other stages, the hair transplant is the primary intervention; at still others, the combination produces the best long-term outcome. The consultation combines scalp analysis, donor mapping, and family history to arrive at an individual plan.

What Happens During a Session? From Blood Draw to Leaving the Clinic

Let us walk through a hair PRP session by answering the question: "What actually happens in 60–75 minutes?" In practice, the session follows this sequence:

1. Blood draw (5–10 min). Twenty millilitres of blood are drawn from your arm — exactly as in a routine blood test — and transferred into a CE-marked, single-use, closed-system PRP collection tube. The tube contains an anticoagulant and a separating gel.

2. Centrifugation (10–15 min). The tube is spun in a calibrated medical centrifuge at the speed and duration specified by the kit manufacturer. The blood separates into three layers. The patient rests in the room during this time.

3. PRP separation (3–5 min). The platelet-rich middle layer is drawn into a sterile syringe. Each session yields 4–6 ml of ready-to-use PRP. Some protocols add calcium chloride for activation; this is not mandatory and is a matter of clinical preference.

4. Topical anaesthesia (15–20 min — optional). An anaesthetic cream or cooling spray is applied to the scalp. A significant proportion of patients tolerate the procedure without anaesthesia; the choice is yours.

5. Injection (30–45 min). Using 30-gauge fine needles, 0.05–0.1 ml of PRP is delivered at each point in a 1 cm grid pattern to the dermis–subcutaneous boundary. In males, the frontotemporal recession and vertex are targeted; in females, the injection follows the central hair part. Each session involves 40–80 injection points.

6. Cooling and discharge (5–10 min). Post-procedure instructions are given and the patient leaves. Shampooing is deferred for the first 24 hours; intense exercise and sauna are avoided for the first 48 hours; direct sun exposure is minimised for the first seven days.

Pain experience. Most patients describe the session as "acceptable discomfort." The needles are very fine (30G) and the injections are quick. Topical anaesthesia reduces discomfort noticeably. In the first 24 hours after the session, mild scalp tenderness, redness, and occasionally a mild headache may occur — all manageable with paracetamol. Ibuprofen and other NSAIDs are avoided for the first 48 hours, as they affect platelet function.

You can return to normal daily activities immediately after the session. Hair PRP is not a surgical procedure requiring recovery time; it is an in-clinic treatment.

Vampire Scalp and Facial PRP: Three Things That Should Not Be Confused

Although marketing uses the single word "PRP," in practice we are talking about three distinct protocols. Confusion between them is one of the most common errors in expectation management.

1. Hair PRP (standard): The classic protocol. Blood draw → centrifugation → scalp micro-injection in a 1 cm grid pattern. Target: dermal papilla and follicular stem cells. Starting course of 3 sessions, then maintenance every 3–6 months.

2. Vampire Scalp (PRP + microneedling): In addition to PRP injection, motor-driven microneedling (dermaroller) is applied to the scalp. The controlled micro-channels increase PRP penetration and trigger additional growth factor release as the skin undergoes its own healing process. Small studies suggest the combined approach produces a stronger efficacy signal in androgenetic alopecia than standard PRP alone. For detail, see: dermaroller. This is the procedure marketed in the media as "vampire scalp" or "vampire hair."

3. Facial PRP: An entirely separate protocol. The same technology, a different target: dermal fibroblasts, superficial-to-mid dermis, mesotherapy grid pattern. The aim is skin rejuvenation, under-eye correction, and collagen stimulation — not hair. For detail, see: facial PRP.

Hair PRP and facial PRP are not the same thing; volume, needle depth, and injection pattern all differ. When a patient says "I'd like PRP" at the clinic, our first question is: for your hair or your face? Two separate consultations, two separate protocols.

Pricing, Packages, and Marketing Traps

Hair PRP is offered at many centres in Northern Cyprus (TRNC) and prices vary considerably. In the interest of transparency, here are our indicative figures.

Approximate price ranges (Nis Clinic — 2026):

Factors that determine the price: the size of the target area (vertex only, or the full hairline), the PRP kit used, whether microneedling is added, and the choice of topical anaesthesia. A package discount does not mean a reduction in session quality — the kit and protocol used in a package session are identical to those used in a single session.

Marketing traps to avoid:

• "New hair in a single session." Medically inaccurate. A clinical response to PRP emerges at months 3–6; a single-session promise is a failure of expectation management.
• "Miracle results / 100% success / guaranteed outcome." These claims are unethical in health content; the literature does not support them.
• "PRP makes a hair transplant unnecessary." This is true at some stages and false at others — used as a blanket marketing statement, it is misleading.
• An unusually low price for a single session. A CE-marked kit, calibrated centrifuge, sterile field, and physician oversight all carry a baseline cost; a very low price represents a compromise on at least one of these.
• "You will no longer need medication." The literature says the opposite: medication combined with PRP outperforms PRP alone.

Our approach at Nis Clinic. We administer hair PRP under the supervision of Op. Dr. İbrahim Meyzin, using a CE-marked closed-system kit, a calibrated medical centrifuge, and a sterile injection field. Pricing is provided as a written quote after consultation — no items are added afterwards. If assessment shows that PRP is not the right option for you, we do not apply pressure to reverse that conclusion. What is medically correct is not always commercially appealing — that is a line we maintain.